Dashboard

Transgene (Euronext: TNG)

Transgene is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s clinical-stage programs are: TG4001, a therapeutic vaccine against HPV-positive cancers, TG6002, an oncolytic virus for the treatment of solid tumors, TG4050, the first individualized therapeutic vaccine based on the myvac™ platform and BT-001, the first oncolytic virus based on the Invir.IO™ platform.
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.

Corporate presentation (March 2021)

Présentation

Financial calendar

  • March 10, 2021 - 2020 Fiscal Year Results
  • April 27, 2021 - First Quarter 2021 Financial Results
  • May 26, 2021 - Annual Shareholders’ Meeting
  • September 22, 2021 - First Half 2021 Financial Results
  • November 4, 2021 - Third Quarter 2021 Financial Results

Contact

Contact Relations Investisseurs

Lucie Larguier, +33 (0)3 88 27 91 00,

I have read and understood Transgene’s Privacy Policy and I agree to receive updates from Transgene. I understand that I may opt out at any time with the « unsubscribe link » at the foot of any email communication from Transgene or I can contact communication@transgene.fr to request such opting out.

Financial information

Key figures

In € million
except share and per share data
20202019201820172016
Revenue9.913.742.98.110.3
R&D Expense27.3-31.4-27.3-30.4-26.4
G&A Expense-6.5-7.1-7.0-5.7-6.2
Net income (loss)-17.2-18.88.0-32.3-25.2
Net Cash Burn-17.0-20.5-24.5-28.1-30.6
Cash & Cash Equivalents26.343.316.941.456.2
Earnings/Loss per Share (Basic and Diluted)-0.21-0.230.13-0.52-0.45
Shares Outstanding83,841,33483,265,46462,275,92362,075,19056,431,991

Financial reports

YearsQuarterInterimRegistration Document
FirstSecondThirdFourth
2020      
2019      
2018      
2017      
2016      
2015        
2014      

Regulated information

Stock information

General

Stock MarketEuronext Paris – Eurolist (compartiment B)
Reuters / BloombergTRNG.PA / TNG.FP
ISIN CodeFR0005175080
Total number of shares outstanding83,841,334
Initial Public Offering (IPO)March 26, 1998
Local Sector IndexNext Biotech / CAC Mid 100
Financial Year EndsDecember 31


Stock price

Loading…


Shareholder structure

graphe structure de l'actionnariat

Analysts

CompanyAnalystE-mailPhone
Bryan Garnier & Co. LtdJean-Jacques Le Furjjlefur@bryangarnier.com+33 (0)1 70 36 57 45
Intron HealthNaresh Chouhannaresh@intronhealthresearch.com+44 207 375 9143
Invest SecuritiesJamila El Bougrinijelbougrini@invest-securities.com+33 (0)1 44 88 88 09
Kempen & Co.Suzanne van Voorthuizensuzanne.vanvoorthuizen@kempen.com+31 (0)20 348 8484
Kepler CheuvreuxArsene Guekam
Kepler’s research can be accessed here
aguekam@keplercheuvreux.com+33 1 70 98 85 27
Life Science Capital LLCJacques A. Villefrancjacques@lifesciadvisors.com+1 646 597-6997
Oddo BHFMartial Descouturesmartial.descoutures@oddo-bhf.com+33 (0)1 44 51 85 00

Any opinions, forecasts, estimates, projections or predictions regarding Transgene’s performance made by the analysts are theirs alone and do not necessarily represent the opinions, forecasts, estimates, projections or predictions of Transgene or its management. By providing the names of the analysts or certain information from them, Transgene does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. Transgene assumes no liability for the accuracy of such information and undertakes no obligation to update it.

Investor Events & Presentations

Financial calendar

  • March 10, 2021 - 2020 Fiscal Year Results
  • April 27, 2021 - First Quarter 2021 Financial Results
  • May 26, 2021 - Annual Shareholders’ Meeting
  • September 22, 2021 - First Half 2021 Financial Results
  • November 4, 2021 - Third Quarter 2021 Financial Results

Investor events

  • January 6, 2021 - 10th Annual LifeSci Advisors Corporate Access Event: January 6 to 14, 2021 – Virtual event
  • January 7, 2021 - Oddo BHF Digital Forum: January 7 to 13, 2021 – Virtual event
  • January 26, 2021 - Biomed Event: January 26 & 27, 2021 – Virtual event

Corporate governance

Transgene complies with the corporate governance recommendations of the MiddleNext Code of Governance for Mid and Small Caps (the Code) (Code de gouvernement d’entreprise des valeurs moyennes et petites de MiddleNext). MiddleNext is an independent society representing midcap public issuers; the Code is largely referred to by small, mid and even large cap firms and accepted by regulators as guidance for best governance practices.

Board of Directors

The Board of Directors is currently composed of ten members, elected for renewable three-year terms. Six members of the Board are independent directors as defined in the Code. The Board is chaired by the Chairman and Chief Executive Officer. The Board has adopted a charter of internal regulations that governs the conduct of the Board of Directors and its committees. Detailed information can be found in the Registration Document.

The Board of Directors is assisted by two committees:

The Audit Committee is composed of four directors of the Board, three of whom are independent. The Vice President Finance is invited to attend each Committee meeting to present the financial situation of the Company. The Audit Committee’s operations are governed by a charter that is reviewed regularly. The committee regularly reports on its work and provides recommendations to the Board of Directors.
The Compensation Committee is composed of two independent directors and is responsible for recommending to the Board of Directors the salaries, bonuses and share-based compensation to executives and key personnel of the Company.

Management Committee

The Management Committee is a non-statutory body that oversees the Company’s daily operations and ensures, in all managerial aspects, that the Company’s strategy is properly executed in accordance with its objectives. The committee is composed of nine members
The Company has established a number of other internal bodies and procedures, for example, for financial controlling, project management and risk management.

.

Annual General Meeting

Annual General Meeting of May 27, 2020
ORDINARY AND EXTRAORDINARY MEETING

Location
TRANSGENE
400 boulevard Gonthier d’Andernach – Parc d’Innovation
67400 ILLKIRCH-GRAFFENSTADEN – FRANCE

Date and Time

27 May 2021 à 10am behind closed doors
Live broadcast  (soon…)

Documents

French BALO publication